US 11,780,925 B2
ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
Mark Throsby, Utrecht (NL); Cecilia Anna Wilhelmina Geuijen, Utrecht (NL); David Andre Baptiste Maussang-Detaille, Utrecht (NL); and Ton Logtenberg, Utrecht (NL)
Appl. No. 16/499,185
Filed by Merus N.V., Utrecht (NL)
PCT Filed Apr. 3, 2018, PCT No. PCT/NL2018/050206
§ 371(c)(1), (2) Date Sep. 27, 2019,
PCT Pub. No. WO2018/182422, PCT Pub. Date Oct. 4, 2018.
Claims priority of application No. 17164292 (EP), filed on Mar. 31, 2017.
Prior Publication US 2020/0102393 A1, Apr. 2, 2020
Int. Cl. C07K 16/28 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/2863 (2013.01) [C07K 16/468 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01)] 15 Claims
 
1. A method of treating a cancer in a subject, wherein the cancer comprises an ErbB-2 and ErbB-3 positive cancer cell, the method comprising administering a bispecific antibody that comprises a first antigen-binding site that can bind an extracellular part of ErbB-2, and a second antigen-binding site that can bind an extracellular part of ErbB-3 to the subject, wherein the cell comprises an NRG1 fusion gene comprising at least a portion of the NRG1-gene fused to a sequence from a different chromosomal location;
the first antigen-binding site comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:40, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:41, and a heavy chain CDR3 comprising the amino acid sequence SEQ ID NO:42;
the second antigen-binding site comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:54, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:55, and a heavy chain CDR3 comprising the amino acid sequence SEQ ID NO:56; and
wherein the first antigen binding site and the second antigen binding site comprise a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:75, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:76, and a light chain CDR3 comprising the amino acid sequence SEQ ID NO:77.